Preprint Published: Hemera’s REMaST Research Marks a Breakthrough in Nerve Regeneration

Dec 23, 2024 | News

We are pleased to announce the preprint publication of the scientific article presenting the results of our groundbreaking research on the REMaST therapy, developed to promote the regeneration of damaged nervous tissue. The study highlights a previously unknown role...

Hemera Among the Top 8 Health Startups

Nov 22, 2024 | News

We are proud to announce that Hemera has been included in the list of the 8 emerging startups revolutionizing the healthcare sector, as reported by Milano Finanza. This recognition highlights our commitment to innovation and the development of advanced therapeutic...

Hemera Wins the 2024 Italian Master Startup Award in the Life Sciences MED-Tech Category

Sep 25, 2024 | News

Hemera has been named co-winner of the 2024 IMSA – Italian Master Startup Award in the Life Sciences MED-Tech category, alongside ALBA Robot. The award highlights the most promising and innovative startups in Italy. It is organized by the PNICube Association in...

Hemera Named Finalist at the 2024 Italian Master Startup Award

Sep 6, 2024 | News, Press Releases

We are pleased to announce that Hemera has been selected as one of the 11 finalists for the Italian Master Startup Award (IMSA), the prestigious prize dedicated to scale-ups born from academic research. The award is promoted by the national network of university...

Hemera Presents the Progress of REMaST®️ Therapy at the FENS Forum 2024

Jun 28, 2024 | News, Press Review

We are excited to announce our participation in the FENS Forum 2024, the largest European congress dedicated to neuroscience, taking place from June 25 to 29 in Vienna. The teams from the Therapy Development Department and the Research and Development Department,...

We are pleased to welcome Humanitas Mirasole S.p.A. among Hemera’s shareholders

Jun 27, 2024 | News

We are pleased to announce that Istituto Clinico Humanitas Mirasole S.p.A. has joined Hemera’s shareholding structure, acquiring a 1.5% stake in the company. Humanitas is a highly specialized teaching and research hospital, accredited by the Italian National Health...